The White House now scheduled a total of four meetings with cannabis industry and research stakeholders this week to discuss a proposed enforcement policy for CBD products.
The Office of Information and Regulatory Affairs (OIRA) under the White House Office of Management and Budget (OMB) announced earlier this month that it plans to review yet-unpublished guidance titled “Cannabidiol (CBD) Products Compliance and Enforcement Policy” that was submitted by the Food and Drug Administration (FDA).
Interested parties are able to request meetings to discuss the issue—and now four meetings have been set for April 1-2.
David Heldreth, CEO of Panacea Plant Sciences, was the first to secure a meeting with OIRA, and he told Marijuana Moment last week he intends to use the opportunity to encourage FDA to develop more holistic guidance around CBD that goes beyond isolates of the cannabinoid.
Since then, the White House has accepted requests for meetings to discuss the yet-to-be-published CBD rule with Trent Woloveck of the multi-state cannabis operator Jushi Holdings on Wednesday, as well as Mackie Barch of Story Cannabis and Iowa hemp farmer Earl Ramey on Thursday.
All of this comes months before changes to federal hemp laws are set to significantly shake up the
Read full article on Marijuana Moment
